STOCK TITAN

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Cyclacel Pharmaceuticals announced participation in the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022. The event will take place at 9:30 AM ET in Track 2, St Germain III, New York. A fireside chat presentation format will be used. Cyclacel is focused on developing innovative cancer treatments, particularly through its lead candidates, fadraciclib and CYC140, targeting solid tumors and hematological malignancies. For further details, visit cyclacel.com.

Positive
  • None.
Negative
  • None.

BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in Ladenburg Thalmann’s 2022 Healthcare Conference on September 29, 2022 at the Sofitel New York.

Event:Ladenburg Thalmann 2022 Healthcare Conference
Date:Thursday, September 29, 2022
Time/location:9:30am ET, Track 2, St Germain III
Format:Fireside Chat Presentation
Webcast:Link

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.

Contacts

Company:Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com
Investor Relations:Irina Koffler, LifeSci Advisors, LLC, (646) 970-4681, ikoffler@lifesciadvisors.com

© Copyright 2022 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.


FAQ

When is Cyclacel Pharmaceuticals participating in the Ladenburg Thalmann 2022 Healthcare Conference?

Cyclacel Pharmaceuticals will participate in the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022.

What time is Cyclacel's presentation at the Ladenburg Thalmann 2022 Healthcare Conference?

Cyclacel's presentation at the Ladenburg Thalmann 2022 Healthcare Conference is scheduled for 9:30 AM ET.

Where will the Ladenburg Thalmann 2022 Healthcare Conference take place?

The Ladenburg Thalmann 2022 Healthcare Conference will be held at the Sofitel New York.

What is the format of Cyclacel's presentation at the conference?

Cyclacel's presentation at the conference will be in the format of a fireside chat.

What are Cyclacel Pharmaceuticals' main drug candidates mentioned in the press release?

The main drug candidates mentioned are fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor.

What is the stock symbol for Cyclacel Pharmaceuticals?

The stock symbols for Cyclacel Pharmaceuticals are CYCC and CYCCP.

Cyclacel Pharmaceuticals, Inc

NASDAQ:CYCC

CYCC Rankings

CYCC Latest News

CYCC Stock Data

2.00M
6.19M
4.82%
18.03%
3.1%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BERKELEY HEIGHTS